Asston Pharmaceuticals Ltd (APL) — shareholding pattern, promoter holding, financials and share price
About Asston Pharmaceuticals Ltd (APL)
Asston Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as APL and on the BSE under scrip code 544445. Its ISIN is INE0SJX01015.
Incorporated in 2019, Asston Pharmaceuticals Ltd is in the business of manufacturing pharmaceutical products. [1]
Listed peers in Pharmaceuticals: Source Natural Foods & Herbal Supplements Ltd, Vilin Bio Med Ltd, Onyx Biotec Ltd, Phaarmasia Ltd, Ajooni Biotech Ltd, Vineet Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹76.5 a share on 10 Jul 2026, Asston Pharmaceuticals Ltd (APL) was valued at a price-to-earnings ratio of 16.85x against an industry P/E of 36.41x and a price-to-book of 1.68x on a book value of ₹45.65 per share. Solomo computes return on equity of 9.95% and return on capital employed of 11.89% from filed results.
- P/E
- 16.85x
- Industry P/E
- 36.41x
- P/B
- 1.68x
- EPS (TTM)
- ₹4.54
- Book value / share
- ₹45.65
- ROE
- 9.95%
- ROCE
- 11.89%
- ROA
- 0.99%
- Debt / equity
- 0.13x
- Dividend yield
- 0%
- EBITDA margin
- 8.64%
- 52-week range
- ₹61.02 – ₹126
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Asston Pharmaceuticals Ltd (APL) reported revenue of ₹25.47 crore, net profit of ₹3.87 crore and earnings per share of ₹4.55. That compares with revenue of ₹25.04 crore and net profit of ₹3.85 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹10.05 crore and net profit ₹0.48 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 9.6 | 6.54 | 16.03 | 25.04 | 25.47 |
| Net profit (₹ cr) | 0.11 | 1.06 | 2.43 | 3.85 | 3.87 |
| EPS (₹) | 1.57 | 15.14 | 31 | 6.14 | 4.55 |
| Measure | 3Y | 1Y |
|---|---|---|
| Sales growth | 37.66% | 56.21% |
| Profit growth | 226.59% | 58.44% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 50.66% of Asston Pharmaceuticals Ltd (APL), foreign institutional investors (FII) hold 1.91%. Market capitalisation was ₹65 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2025.
Largest disclosed public shareholders in Mar 2026: MAHESH VISHNUPANT MULAY 2.91%, KULDIP SINGH RATHEE 2.35%, HUF 2.28%, MINERVA VENTURES FUND 1.91%, VRUSHALI YOGESH SUPEKAR 1.46%, DILIP RAMESHCHANDRA JAGAD 1.25%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 50.66% | - | 1.91% | - | 49.34% |
| Sep 2025 | 50.66% | - | 6.04% | - | 49.34% |